Jefferies Group’s Alaunos Therapeutics TCRT Stock Holding History

Jefferies Group’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-1,511	Closed	-$2.44M	–	3491
2015 Q1	$2.44M	Buy	+1,511	New	+$2.24M	0.01%	682

Other funds holding TCRT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jefferies Group's TCRT Position: Q1 2020 in Review

Jefferies Group sold out of Alaunos Therapeutics (TCRT) in Q1 2020, closing a stake of 130 shares — an estimated $92K sold.

Jefferies Group first reported a position in TCRT in Q2 2015 and held it in 5 quarters. The position peaked at $310K in Q3 2018. 146 funds tracked by Wall St. Rank hold TCRT as of Q1 2020.

Jefferies Group reported no remaining Alaunos Therapeutics position as of Q1 2020 after selling out during the quarter.
Jefferies Group sold 130 Alaunos Therapeutics shares in Q1 2020, an estimated $92K.
Jefferies Group first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 5 quarters.
Jefferies Group's Alaunos Therapeutics position peaked at $310K in Q3 2018.
146 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2020.

Based on Jefferies Group's 13F filing for Q1 2020, filed 15 May 2020.